Compare SSII & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SSII | TBPH |
|---|---|---|
| Founded | N/A | 2013 |
| Country | India | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.0B |
| IPO Year | N/A | N/A |
| Metric | SSII | TBPH |
|---|---|---|
| Price | $3.98 | $20.28 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $27.80 |
| AVG Volume (30 Days) | 112.0K | ★ 358.2K |
| Earning Date | 03-20-2026 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.58 |
| Revenue | $36,066,457.00 | ★ $80,327,000.00 |
| Revenue This Year | N/A | $70.78 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $35.29 |
| Revenue Growth | ★ 158.36 | 27.12 |
| 52 Week Low | $3.02 | $7.90 |
| 52 Week High | $22.42 | $21.03 |
| Indicator | SSII | TBPH |
|---|---|---|
| Relative Strength Index (RSI) | 29.30 | 53.35 |
| Support Level | $3.40 | $18.78 |
| Resistance Level | $6.01 | $20.50 |
| Average True Range (ATR) | 0.52 | 0.78 |
| MACD | -0.15 | -0.08 |
| Stochastic Oscillator | 11.46 | 44.00 |
SS Innovations International Inc is a commercial-stage surgical robotics company focused on transforming patient lives by democratizing access to advanced surgical robotics technologies. The company designs, manufactures, and markets an advanced, next-generation, and affordable surgical robotic system called the SSi Mantra, and the instruments and accessories used with SSi Mantra to perform a wide range of soft-tissue, robotically assisted surgeries. The company earns the majority of its revenue from India.
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).